Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02673398
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:06.736947+00:00
Published At
2022-03-16T00:00:00+00:00
Record Updated At
2023-06-18
Results Posted At
2022-03-16
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["HER2 Positive Breast Carcinoma", "Stage IV Breast Cancer AJCC v6 and v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-06-18"
protocolSection.identificationModule.nctId
"NCT02673398"
protocolSection.identificationModule.officialTitle
"Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2022-03-16"

Study condition terms

  • HER2 Positive Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IV Breast Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.